Abstract:Objectives: Despite FDA approval of pembrolizumab in microsatellite instability-high (MSI-H) / mismatch repair deficient solid tumors, approximately half of patients with MSI-H endometrial cancer are treatment-refractory. Our unpublished analysis of MSI-H endometrial cancer samples from the Cancer Genome Atlas (TCGA) suggests the possibility of immunologically 'hot' and 'cold' tumor microenvironments (TME); these differences may explain variable treatment responses. We sought to evaluate MSI-H endometrial tumor samples to examine differences in the TME and identify transcriptomic signatures associated with response/resistance to pembrolizumab. Methods: Archival tumor samples from MSI-H endometrial cancer patients treated at the University of Texas MD Anderson Cancer Center were obtained under an IRB-approved protocol. Tissue samples originating from patients who did not receive pembrolizumab treatment ('untreated cohort'; n=11) were submitted for RNA sequencing analysis (RNA-seq) to evaluate TCGA-derived signatures in an independent sample set. Pre-treatment archival tumor samples ('treated cohort'; n=23) from patients who were later treated with pembrolizumab were collected and submitted for RNA-seq to identify predictive immuno-genomic signatures associated with treatment response. Results: In the untreated cohort, there were observable differences in the transcriptomic profiles of the samples. Four samples were immunologically 'hot' as evidenced by an abundance of pro-inflammatory immune cell infiltrate (CD8+ T-cells, B-cells, monocytes, and dendritic cells). Three samples had a paucity of pro-inflammatory immune cell infiltrate ('cold') while 4 samples had intermediate amounts ('warm'). In the treated cohort, there were 14 responders, 7 non-responders, and 2 patients with unknown response. The 14 responders consisted of samples with 'hot' (5/5; 100%), 'cold' (6/8; 75%), and 'warm' TMEs (3/8; 37.5%) while the 7 non-responders consisted of only 'cold' (2/8; 25%) and 'warm' (5/8; 62.5%) TME samples. We observed an enrichment of fibroblasts and endothelial cell transcriptomic signatures in the samples of the non-responders compared to responders (p=0.018). In particular, there was a significantly higher gene expression of PAMR1, HHIP, and MMRN1 in the non-responders. Subdividing samples into complete response, partial response, and no response to pembrolizumab, we observed a trend of increasing enrichment of fibroblast and endothelial cell transcriptomic signatures as response decreased. Specifically, there was increasing expression of TAGLN (fibroblast gene) and other endothelial cell genes (EMCN, KDR, MMRN1, MYCT1, PEAR1, PTPRB, and TEK). Conclusions: The TME composition appears to be heterogeneous among MSI-H endometrial cancer patients. Increased presence of fibroblasts and endothelial cells in the TME may contribute to innate resistance to pembrolizumab. Treatment aimed toward the reduction of these cellular subpopulations may improve sensitivity to PD-1 inhibitors. Future studies are needed to validate these findings. Despite FDA approval of pembrolizumab in microsatellite instability-high (MSI-H) / mismatch repair deficient solid tumors, approximately half of patients with MSI-H endometrial cancer are treatment-refractory. Our unpublished analysis of MSI-H endometrial cancer samples from the Cancer Genome Atlas (TCGA) suggests the possibility of immunologically 'hot' and 'cold' tumor microenvironments (TME); these differences may explain variable treatment responses. We sought to evaluate MSI-H endometrial tumor samples to examine differences in the TME and identify transcriptomic signatures associated with response/resistance to pembrolizumab. Archival tumor samples from MSI-H endometrial cancer patients treated at the University of Texas MD Anderson Cancer Center were obtained under an IRB-approved protocol. Tissue samples originating from patients who did not receive pembrolizumab treatment ('untreated cohort'; n=11) were submitted for RNA sequencing analysis (RNA-seq) to evaluate TCGA-derived signatures in an independent sample set. Pre-treatment archival tumor samples ('treated cohort'; n=23) from patients who were later treated with pembrolizumab were collected and submitted for RNA-seq to identify predictive immuno-genomic signatures associated with treatment response. In the untreated cohort, there were observable differences in the transcriptomic profiles of the samples. Four samples were immunologically 'hot' as evidenced by an abundance of pro-inflammatory immune cell infiltrate (CD8+ T-cells, B-cells, monocytes, and dendritic cells). Three samples had a paucity of pro-inflammatory immune cell infiltrate ('cold') while 4 samples had intermediate amounts ('warm'). In the treated cohort, there were 14 responders, 7 non-responders, and 2 patients with unknown response. The 14 responders consisted of samples with 'hot' (5/5; 100%), 'cold' (6/8; 75%), and 'warm' TMEs (3/8; 37.5%) while the 7 non-responders consisted of only 'cold' (2/8; 25%) and 'warm' (5/8; 62.5%) TME samples. We observed an enrichment of fibroblasts and endothelial cell transcriptomic signatures in the samples of the non-responders compared to responders (p=0.018). In particular, there was a significantly higher gene expression of PAMR1, HHIP, and MMRN1 in the non-responders. Subdividing samples into complete response, partial response, and no response to pembrolizumab, we observed a trend of increasing enrichment of fibroblast and endothelial cell transcriptomic signatures as response decreased. Specifically, there was increasing expression of TAGLN (fibroblast gene) and other endothelial cell genes (EMCN, KDR, MMRN1, MYCT1, PEAR1, PTPRB, and TEK). The TME composition appears to be heterogeneous among MSI-H endometrial cancer patients. Increased presence of fibroblasts and endothelial cells in the TME may contribute to innate resistance to pembrolizumab. Treatment aimed toward the reduction of these cellular subpopulations may improve sensitivity to PD-1 inhibitors. Future studies are needed to validate these findings.

Abstract PO015: The impact of the tumor immune microenvironment on response to pembrolizumab in patients with microsatellite instability-high endometrial cancer

Abstract 1248: Predictors of Innate Resistance to Pembrolizumab in Patients with Microsatellite Instability-High Endometrial Cancer

The Tumor Immune Microenvironment Shapes Response to Pembrolizumab in Microsatellite Instability-High Endometrial Cancer

Abstract 1145: Comparative spatial transcriptomic analysis of tumor microenvironment responses to conventional chemotherapy and immunotherapy in triple-negative breast cancer

Abstract 2486: Dissecting tumor-immune interaction in response and resistance to immune checkpoint blockade in metastatic melanoma

Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer

Abstract 955: Proteogenomic insights suggest druggable pathways in endometrial cancer

Abstract 5149: Extracellular matrix remodeling in metastatic mismatch repair deficient endometrial cancer:Implications for immune checkpoint inhibitor response prediction

Abstract B083: Single-cell and spatial transcriptomic characterization of treatment resistance and immune dynamics in high-grade serous ovarian cancer

Abstract 4969: Investigating digital pathology tumor microenvironment features for immunotherapy outcome in patients with advanced non-small cell lung cancer

Abstract P1-04-03: Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1

Abstract PO4-06-04: Understanding metastasis mixed-treatment responses through genomic analyses

Abstract 2803: Identification of microbiome and predictive immune biomarkers in patients with advanced non-small lung cancer treated with pembrolizumab with or without chemotherapy

Abstract 2680: Exploration of tumor environment classification using mIHC in pan-cancer tissue samples

Abstract 71: Differential infiltration of key immune cell populations across malignancies varying by immunogenic potential and likelihood of response to immunotherapy

Abstract 625: Remodeling of the tumor microenvironment in esophageal squamous cell carcinoma by neoadjuvant immunochemotherapy and its impact on therapeutic efficacy

Abstract CT141: Combination of hormone therapy, GnRH agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2- metastatic breast cancer patients: Results of biomarker analysis from a pilot phase II study

Abstract 1175: Differential patterns of immune infiltration in the tumor immune microenvironment associate with therapeutic response in primary prostate cancer following chemohormonal therapy

Abstract 79: Study of tumor microenvironment of ovarian clear cell carcinoma

Abstract 7036: Integrative biomarker profiling for predicting immunotherapy outcomes in gynecologic cancers

Abstract CT207: Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629